The Management of Acute Pulmonary Arterial Hypertension

Cardiovascular Therapeutics

Volumn 29, Issue 3, 2011, Pages 153-175

  Hui li, Gan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Pulmonary arterial hypertension (PAH); Right heart failure

Indexed keywords

AMBRISENTAN; BIOLOGICAL MARKER; BOSENTAN; DOBUTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; INOTROPIC AGENT; ISOPRENALINE; MILRINONE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; SILDENAFIL; SITAXSENTAN; VASODILATOR AGENT; VASOPRESSIN;

ACUTE DISEASE; ARTICLE; CARDIOPULMONARY BYPASS; CHRONIC DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEART RIGHT VENTRICLE PRESSURE; HUMAN; KIDNEY DISEASE; LUNG TRANSPLANTATION; MULTIPLE CYCLE TREATMENT; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SINGLE DRUG DOSE;

ACUTE DISEASE; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR PRESSURE;

EID: 79955880827     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00095.x     Document Type: Article

References (192)

1. Barberà JA, Escribano P, Morales P, Gómez MA, Oribe M, Martínez A, Román A, Segovia J, Santos F, Subirana MT. Sociedad Española de Neumología y Cirugía Torácica; Sociedad Española de Cardiología. [Standards of care in pulmonary hypertension. Consensus statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC)]. Rev Esp Cardiol 2008;61:170-184.
2. McGoon MD, Kane GC. Pulmonary hypertension: Diagnosis and management. Mayo Clin Proc 2009;84:191-207.
3. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF (AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2009;53:1573-1619.
4. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK. Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987;107:216-223.
5. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S-24S.
6. Moloney ED, Evans TW. Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome. Eur Respir J 2003;21:720-727.
7. Albertini M, Ciminaghi B, Mazzola S, Clement MG. Improvement of respiratory function by bosentan during endotoxic shock in the pig. Prostaglandins Leukot Essent Fatty Acids 2001;65:103-108.
8. Wort SJ, Evans TW. The role of the endothelium in modulating vascular control in sepsis and related conditions. Br Med Bull 1999;55:30-48.
9. Lambermont B, Kolh P, Detry O, Gerard P, Marcelle R, D'Orio V. Analysis of endotoxin effects on the intact pulmonary circulation. Cardiovasc Res 1999;41:275-281.
10. Via G, Braschi A. Pathophysiology of severe pulmonary hypertension in the critically ill patient. Minerva Anestesiol 2004;70:233-237.
11. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 2004;43:405-409.
12. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: Pathophysiology and anesthetic approach. Anesthesiology 2003;99:1415-1432.
13. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005;16:13-18.
14. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-725.
15. Hoeper MM, Galié N, Murali S, Olschewski H, Rubenfire M, Robbins IM, Farber HW, McLaughlin V, Shapiro S, Pepke-Zaba J, et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:341-344.
16. Vieillard-Baron A, Schmitt JM, Augarde R, Fellahi JL, Prin S, Page B, Beauchet A, Jardin F. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: Incidence, clinical implications, and prognosis. Crit Care Med 2001;29:1551-1555.
17. Leeman M. Pulmonary hypertension in acute respiratory distress syndrome. Monaldi Arch Chest Dis 1999;54:146-149.
18. Jardin F, Vieillard-Baron A. Is there a safe plateau pressure in ARDS? The right heart only knows. Intensive Care Med 2007;33:444-447.
19. Sibbald WJ, Paterson NA, Holliday RL, Anderson RA, Lobb TR, Duff JH. Pulmonary hypertension in sepsis: Measurement by the pulmonary arterial diastolic-pulmonary wedge pressure gradient and the influence of passive and active factors. Chest 1978;73:583-591.
20. Kostrubiec M, Pedowska-Włoszek J, Ciurzyński M, Bienias P, Pacho S, Piaskowska M, Pruszczyk P. Endothelin is not elevated in acute pulmonary embolism. Thromb Res 2009. [Epub ahead of print].
21. Romand JA, Donald FA, Suter PM. Cardiopulmonary interactions in acute lung injury: Clinical and prognostic importance of pulmonary hypertension. w Horiz 1994;2:457-462.
22. Moloney ED, Evans TW. Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome. Eur Respir J 2003;21:720-727.
23. Luhr O, Nathorst-Westfelt U, Lundin S, Wickerts CJ, Stiernström H, Berggren L, Aardal S, Johansson LA, Stenqvist O, Rudberg U, et al. A retrospective analysis of nitric oxide inhalation in patients with severe acute lung injury in Sweden and Norway 1991-1994. Acta Anaesthesiol Scand 1997;41:1238-1246.
24. Goldsmith JA, Kavanagh BP, Pearl RG. Plasma potentiates the priming effects of endotoxin on platelet activating factor-induced pulmonary hypertension in the rabbit lung. Anesth Analg 1996;83:242-246.
25. Clavijo LC, Carter MB, Matheson PJ, Wills-Frank LA, Wilson MA, Wead WB, Garrison RN. Platelet-activating factor and bacteremia-induced pulmonary hypertension. J Surg Res 2000;88:173-180.
26. Snapper JR, Thabes JS, Lefferts PL, Lu W. Role of endothelin in endotoxin-induced sustained pulmonary hypertension in sheep. Am J Respir Crit Care Med 1998;157:81-88.
27. Bernstein AD, Parsonnet V. Bedside estimation of risk as an aid for decision-making in cardiac surgery. Ann Thorac Surg 2000;69:823-828.
28. Subramaniam K, Yared JP. Management of pulmonary hypertension in the operating room. Semin Cardiothorac Vasc Anesth 2007;11:119-136.
29. Wynne R, Botti M. Postoperative pulmonary dysfunction in adults after cardiac surgery with cardiopulmonary bypass: Clinical significance and implications for practice. Am J Crit Care 2004;13:384-393.
30. Ocal A, Kiriş I, Erdinç M, Peker O, Yavuz T, Ibrişim E. Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension. Tohoku J Exp Med 2005;207:51-58.
31. Milot J, Perron J, Lacasse Y, Létourneau L, Cartier PC, Maltais F. Incidence and predictors of ARDS after cardiac surgery. Chest 2001;119:884-888.
32. Coe PF. Managing pulmonary hypertension in heart transplantation: meeting the challenge. Crit Care Nurse 2000;20:22-28, quiz 29-30.
33. Jean-Pierre C, Sébastien R, Medhi S, Bruno S, Patricia D, Yves B, Paul Michel M, Jean-Pierre V. Acute pulmonary hypertension after cardiopulmonary bypass in pig: The role of endogenous endothelin. Eur J Cardiothorac Surg 1999;15:346-352.
34. Urdaneta F, Lobato EB, Beaver T, Muehlschlegel JD, Kirby DS, Klodell C, Sidi A. Treating pulmonary hypertension post cardiopulmonary bypass in pigs: Milrinone vs. sildenafil analog. Perfusion 2008;23:117-125.
35. Sidi A, Naik B, Urdaneta F, Muehlschegel JD, Kirby DS, Lobato EB. Treatment of ethanol-induced acute pulmonary hypertension and right ventricular dysfunction in pigs, by Sildenafil analogue(UK343-664) or nitroglycerin. Annals of Cardiac Anaesthesia 2008;112:96-103.
36. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 2002;54:404-409.
37. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. EurHeart J 2004;25:2243-2278.
38. Chemla D, Castelain V, Hervé P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002;20:1314-1331.
39. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, LeJemtel TH, Cotter G, SHOCK Investigators. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J Am Coll Cardiol 2004;44:340-348.
40. Bossone E, Bodini BD, Mazza A, Allegra L. Pulmonary arterial hypertension: The key role of echocardiography. Chest 2005;127:1836-1843.
41. McConnell MV, Solomon SD, Rayan ME, Come PC, Goldhaber SZ, Lee RT. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol 1996;78:469-473.
42. Engelke C, Rummeny E, Marten K. Acute pulmonary embolism: Prediction of cor pulmonale and short-term patient survival from assessment of cardiac dimensions in routine multidetector-row CT. Rofo 2006;178:999-1006.
43. Karski JM. Transesophageal echocardiography in the intensive care unit. Semin Cardiothorac Vasc Anesth 2006;10:162-166.
44. Schneider C, Schwemmer U, Kredel M, Frommer M, Wurmb T, Greim C, Roewer N, Brederlau J. Handheld vs. conventional transesophageal echocardiography in non-cardiac surgical intensive care unit patients. Ultraschall Med 2008;29:531-534.
45. Cotrim C, Miranda R, Loureiro MJ, Almeida S, Lopes L, Almeida AR, Fernandes R, Simões O, Cordeiro A, Cordeiro P, et al. Echocardiography during treadmill exercise testing for evaluation of pulmonary artery systolic pressure: Advantages of the method. Rev Port Cardiol 2008;27:453-461.
46. Kouzu H, Nakatani S, Kyotani S, Kanzaki H, Nakanishi N, Kitakaze M. Noninvasive estimation of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension. Am J Cardiol 2009;103:872-876. Epub 2009 Jan 24.
47. Haddad F, Zamanian R, Beraud AS, Schnittger I, Feinstein J, Peterson T, Yang P, Doyle R, Rosenthal D. A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr 2009. [Epub ahead of print]
48. Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008;52:1683-1692.
49. Kovacs G, Reiter G, Reiter U, Rienmüller R, Peacock A, Olschewski H. The emerging role of magnetic resonance imaging in the diagnosis and management of pulmonary hypertension. Respiration 2008;76:458-470. Epub 2008 Nov 12.
50. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, Hamada S, Kakishita M, Nakanishi N, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-208.
51. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-870.
52. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, Kolbe T, Schwaiblmair M, Behr J. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-770.
53. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-870.
54. Leuchte HH, El Nounou M, Tuerpe JC, Hartmann B, Baumgartner RA, Vogeser M, Muehling O, Behr J. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007;131:402-409.
55. La Vecchia L, Ottani F, Favero L, Spadaro GL, Rubboli A, Boanno C, Mezzena G, Fontanelli A, Jaffe AS. Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism. Heart 2004;90:633-637.
56. Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003;145:821-825.
57. Sanchez O, Marié E, Lerolle U, Wermert D, Israël-Biet D, Meyer G. Pulmonary arterial hypertension in women. Rev Mal Respir 2008;25:451-460.
58. Jaïs X, Sitbon O, Savale L, Montani D, Humbert M, Simonneau G. Pulmonary arterial hypertension. Rev Prat 2008;58:1997-2010.
59. Desole S, Kähler CM. Decompensated pulmonary hypertension. Dtsch Med Wochenschr 2008;133(Suppl 6):S215-S218. Epub 2008 Sep 23.
60. Jacobs AK, Leopold JA, Bates E, Mendes LA, Sleeper LA, White H, Davidoff R, Boland J, Modur S, Forman R, et al. Cardiogenic shock caused by right ventricular infarction: A report from the SHOCK registry. J Am Coll Cardiol 2003;41:1273-1279.
61. Berisha S, Kastrati A, Goda A, Popa Y. Optimal value of filling pressure in the right side of the heart in acute right ventricular infarction. Br Heart J 1990;63:98-102.
62. Jardin F, Delorme G, Hardy A, Auvert B, Beauchet A, Bourdarias JP. Reevaluation of hemodynamic consequences of positive pressure ventilation: Emphasis on cyclic right ventricular afterloading by mechanical lung inflation. Anesthesiology 1990;72:966-970.
63. Vieillard-Baron A, Loubieres Y, Schmitt JM, Page B, Dubourg O, Jardin F. Cyclic changes in right ventricular output impedance during mechanical ventilation. J Appl Physiol 1999;87:1644-1650.
64. Schmitt JM, Vieillard-Baron A, Augarde R, Prin S, Page B, Jardin F. Positive end-expiratory pressure titration in acute respiratory distress syndrome patients: Impact on right ventricular outflow impedance evaluated by pulmonary artery Doppler flow velocity measurements. Crit Care Med 2001;29:1154-1158.
65. Miranda DR, Klompe L, Cademartiri F, Haitsma JJ, Palumbo A, Takkenberg JJ, Lachmann B, Bogers AJ, Gommers D. The effect of open lung ventilation on right ventricular and left ventricular function in lung-lavaged pigs. Crit Care 2006;10:R86.
66. Reis Miranda D, Gommers D, Struijs A, Meeder H, Schepp R, Hop W, Bogers A, Klein J, Lachmann B. The open lung concept: Effects on right ventricular afterload after cardiac surgery. Br J Anaesth 2004;93:327-332.
67. Balanos GM, Talbot NP, Dorrington KL, Robbins PA. Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography. J Appl Physiol 2003;94:1543-1551.
68. Roberts DH, Lepore JJ, Maroo A, Semigran MJ, Ginns LC. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001;120:1547-1555.
69. Santos C, Ferrer M, Roca J, Torres A, Hernández C, Rodriguez-Roisin R. Pulmonary gas exchange response to oxygen breathing in acute lung injury. Am J Respir Crit Care Med 2000;161:26-31.
70. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007;35:2037-2050.
71. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):645S-687S.
72. Yoshida M, Inoue I, Kawagoe T, Ishihara M, Shimatani Y, Kurisu S, Kusano KF, Ohe T. Novel percutaneous catheter thrombectomy in acute massive pulmonary embolism: Rotational bidirectional thrombectomy (ROBOT). Catheter Cardiovasc Interv 2006;68:112-117.
73. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(Suppl S):13S-24S.
74. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, Jamieson SW, Rubin LJ. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23:595-600.
75. Ulrich S, Speich R, Domenighetti G, Geiser T, Aubert JD, Rochat T, Huber L, Treder U, Fischler M. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly 2007;137:573-580.
76. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-1174.
77. Zwissler B, Welte M., Messmer K. Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction. J Cardiothorac Vasc Anesth 1995;9:283-289.
78. Cockrill BA, Kacmarek RM, Fifer MA, Bigatello LM, Ginns LC, Zapol WM, Semigran MJ. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 2001;119:128-136.
79. Bhorade S, Christenson J, O'connor M, Lavoie A, Pohlman A, Hall JB. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999;159:571-579.
80. Fierobe L, Brunet F, Dhainaut JF, Monchi M, Belghith M, Mira JP, Dall'ava-Santucci J, Dinh-Xuan AT. Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome. Am J Respir Crit Care Med 1995;151:1414-1419.
81. McIntyre RC Jr, Moore FA, Moore EE, Piedalue F, Haenel JS, Fullerton DA. Inhaled nitric oxide variably improves oxygenation and pulmonary hypertension in patients with acute respiratory distress syndrome. J Trauma 1995;39:418-425.
82. Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K Jr, Kelly KM, Smith TC, Small RJ, Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: A randomized controlled trial. Jama 2004;291:1603-1609.
83. Kaisers U, Busch T, Deja M, Donaubauer B, Falke KJ. Selective pulmonary vasodilation in acute respiratory distress syndrome. Crit Care Med 2003;31(4 Suppl):S337-S342.
84. Della Rocca G, Coccia C. Nitric oxide in thoracic surgery. Minerva Anestesiol 2005;71:313-318.
85. George I, Xydas S, Topkara VK, Ferdinando C, Barnwell EC, Gableman L, Sladen RN, Naka Y, Oz MC. Clinical indication for use and outcomes after inhaled nitric oxide therapy. Ann Thorac Surg 2006;82:2161-2169.
86. Deb B, Bradford K, Pearl RG. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit Care Med 2000;28:795-799.
87. Troncy E, Francoeur M, Blaise G. Inhaled nitric oxide: clinical applications, indications, and toxicology. Can J Anaesth 1997;44:973-988.
88. Christenson J, Lavoie A, O'Connor M, Bhorade S, Pohlman A, Hall JB. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med 2000;161:1443-1449.
89. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002;106:1477-1482.
90. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-277.
91. Gomberg-Maitland M., Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31:891-901.
92. Haché M, Denault AY, Bélisle S, Couture P, Babin D, Tétrault F, Guimond JG. Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. Can J Anaesth 2001;48:924-929.
93. Theodoraki K, Rellia P, Thanopoulos A, Tsourelis L, Zarkalis D, Sfyrakis P, Antoniou T. Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth 2002;49:963-967.
94. Domenighetti G, Stricker H, Waldispuehl B. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit Care Med 2001;29:57-62.
95. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonaryhypertension. Ann Intern Med 1996;124:820-824.
96. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J RespirCrit Care Med 1999;160:600-607.
97. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928.
98. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV. Medical therapy for pulmonary arte- rial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
99. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
100. Kerbaul F, Brimioulle S, Rondelet B, Dewachter C, Hubloue I, Naeije R. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med 2007;175:846-850.
101. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-2403.
102. Mikhail GW, Prasad SK, Li W, Rogers P, Chester AH, Bayne S, Stephens D, Khan M, Gibbs JS, Evans TW, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 2004;25:431-436.
103. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: Combined administration with inhaled nitric oxide. Chest 2005;127:1647-1653.
104. Fung E, Fiscus RR, Yim AP, Angelini GD, Arifi AA. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest 2005;128:3065-3073.
105. Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R, Block LH. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123:1293-1295.
106. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-522.
107. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-164.
108. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006;129:417-425.
109. Ng J, Finney SJ, Shulman R, Bellingan GJ, Singer M, Glynne PA. Treatment of pulmonary hypertension in the general adult intensive care unit: A role for oral sildenafil? Br J Anaesth 2005;94:774-777.
110. Trachte AL, Lobato EB, Urdaneta F, Hess PJ, Klodell CT, Martin TD, Staples ED, Beaver TM. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005;79:194-197; discussion 194-197.
111. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006;174:1042-1047.
112. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91:307-310.
113. Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. J Heart Lung Transplant 2007;26:363-369.
114. Aubin MC, Laurendeau S, Mommerot A, Lamarche Y, Denault A, Carrier M, Perrault LP. Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass. J Cardiovasc Pharmacol 2008;51:11-17.
115. Keogh AM, Jabbour A, Hayward CS, Macdonald PS. Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension. Vasc Health Risk Manag 2008;4:1111-1113.
116. Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR, Sheares KK, Hughes R, Morrell NW, Pepke-Zaba J. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008;134:229-236. Epub 2008 Feb 8.
117. Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis 2004;47:34-57.
118. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928.
119. Rich S, Kaufmann E, Levy PS. The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
120. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Elliott CG, Fishman AP, Goldring RM, Groves BM. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989;140:1623-1630.
121. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
122. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Hervé P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111. Epub 2005 Jun 6.
123. Bresser P, Pepke-Zaba J, Jaïs X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension: An evolving treatment paradigm. Proc Am Thorac Soc 2006;3:594-600.
124. Abman SH. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Annu Rev Med 2008. [Epub ahead of print]
125. Steiner MK, Preston IR. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2008;4:943-952
126. Trow TK, Taichman DB. Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism. Respir Med 2009. [Epub ahead of print]
127. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43:1089-1115.
128. Ulrich S, Speich R, Domenighetti G, Geiser T, Aubert JD, Rochat T, Huber L, Treder U, Fischler M. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly 2007;137:573-580.
129. Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 2008;134:775-782. Epub 2008 Jul 14.
130. MacIntyre IM, Dhaun N, Goddard J, Webb DJ. Sitaxsentan sodium for pulmonary hypertension. Drugs Today (Barc) 2008;44:585-600.
131. Macintyre IM, Dhaun N, Goddard J, Webb DJ. Ambrisentan and its role in the management of pulmonary arterial hypertension. Drugs Today (Barc) 2008;44:875-885.
132. Hrometz SL, Shields KM. Role of ambrisentan in the management of pulmonary hypertension. Ann Pharmacother 2008;42:1653-1659. Epub 2008 Oct 28.
133. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-2821.
134. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-1413.
135. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006;145:152-153.
136. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long termimatinib treatment in pulmonary arterial hypertension. Thorax 2006;61:736.
137. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-2019.
138. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failureis a rare event in patients receiving imatinib therapy. Blood 2007;110:1233-1237.
139. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-1413.
140. Yurtseven N, Karaca P, Kaplan M, Ozkul V, Tuygun AK, Aksoy T, Canik S, Kopman E. Effect of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery. Anesthesiology 2003;99:855-858.
141. Fullerton DA, Jaggers J, Jones SD, Brown JM, McIntyre RC Jr. Adenosine for refractory pulmonary hypertension. Ann Thorac Surg 1996;62:874-877.
142. Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001;38:923-931.
143. Ng C, Franklin O, Vaidya M, Pierce C, Petros A. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 2004;5:10-13.
144. Motti A, Tissot C, Rimensberger PC, Prina-Rousso A, Aggoun Y, Berner M, Beghetti M, da Cruz E. Intravenous adenosine for refractory pulmonary hypertension in a low-weight premature newborn: a potential new drug for rescue therapy. Pediatr Crit Care Med 2006;7:380-382.
145. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-1346.
146. Bradford KK, Deb B, Pearl RG. Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbit. J Cardiovasc Pharmacol 2000;36:146-151.
147. Kerbaul F, Rondelet B, Motte S, Fesler P, Hubloue I, Ewalenko P, Naeije R, Brimioulle S. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2004;32:1035-1040.
148. Vizza CD, Rocca GD, Roma AD, Iacoboni C, Pierconti F, Venuta F, Rendina E, Schmid G, Pietropaoli P, Fedele F. Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care 2001;5:355-361.
149. Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med 2004;32(11 Suppl):S455-S465.
150. Kwak YL, Lee CS, Park YH, Hong YW. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension*. Anaesthesia 2002;57:9-14.
151. Hirsch LJ, Rooney MW, Wat SS, Kleinmann B, Mathru M. Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolism. Chest 1991;100:796-801.
152. Brimioulle S, Vachiéry JL, Brichant JF, Delcroix M, Lejeune P, Naeije R. Sympathetic modulation of hypoxic pulmonary vasoconstriction in intact dogs. Cardiovasc Res 1997;34:384-392.
153. Tisdale JE, Patel RV, Webb CR, Borzak S, Zarowitz BJ. Proarrhythmic effects of intravenous vasopressors. Ann Pharmacother 1995;29:269-281.
154. Tritapepe L, Voci P, Cogliati AA, Pasotti E, Papalia U, Menichetti A. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Crit Care Med 1999;27:2180-2183.
155. Meadow WL, Rudinsky BF, Strates E. Selective elevation of systemic blood pressure by epinephrine during sepsis-induced pulmonary hypertension in piglets. Pediatr Res 1986;20:872-875.
156. Holloway EL, Polumbo RA, Harrison DC. Acute circulatory effects of dopamine in patients with pulmonary hypertension. Br Heart J 1975;37:482-485.
157. Prielipp RC, McLean R, Rosenthal MH, Pearl RG. Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. Crit Care Med 1991;19:60-67.
158. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 1993;103:1241-1245.
159. Wallace AW, Tunin CM, Shoukas AA. Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol 1989;257(4 Pt 2):H1228-H1234.
160. Tayama E, Ueda T, Shojima T, Akasu K, Oda T, Fukunaga S, Akashi H, Aoyagi S. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg 2007;6:715-719.
161. Trempy GA, Nyhan DP, Murray PA. Pulmonary vasoregulation by arginine vasopressin in conscious, halothane-anesthetized, and pentobarbital-anesthetized dogs with increased vasomotor tone. Anesthesiology 1994;81:632-640.
162. Leather HA, Segers P, Berends N, Vandermeersch E, Wouters PF. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002;30:2548-2552.
163. Sandoval J, Gaspar J, Pulido T, Bautista E, Martínez-Guerra ML, Zeballos M, Palomar A, Gómez A. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. J Am Coll Cardiol 1998;32:297-304.
164. Reichenberger F, Pepke-Zaba J, McNeil K, Parameshwar J, Shapiro LM. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax 2003;58:797-800.
165. Sandoval J, Rothman A, Pulido T. Atrial septostomy for pulmonary hypertension. Clin Chest Med 2001;22:547-560.
166. Klepetko W, Mayer E, Sandoval J, Trulock EP, Vachiery JL, Dartevelle P, Pepke-Zaba J, Jamieson SW, Lang I, Corris P. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):73S-80S.
167. Ozdogan ME, Erer D, Iriz E, Oktar GL, Kula S, Buyukates M. Right-to-left shunt through a patent foramen ovale left open in the management of acute right heart failure after heart transplantation. J Heart Lung Transplant 2008;27:135-137.
168. Reynolds HR, Hochman JS. Cardiogenic shock: Current concepts and improving outcomes. Circulation 2008;117:686-697.
169. Palevsky HI. Therapeutic options for severe pulmonary hypertension. Clin Chest Med 1997;18:595-609.
170. Aubert S, Leprince P, Bonnet N, Barreda T, Ouattara A, Varnous S, Pavie A, Gandjbakhch I. Limited mechanical circulatory support following orthotopic heart transplantation. Interact Cardiovasc Thorac Surg 2006;5:88-89.
171. Arafa OE, Geiran OR, Andersen K, Fosse E, Simonsen S, Svennevig JL. Intraaortic balloon pumping for predominantly right ventricular failure after heart transplantation. Ann Thorac Surg 2000;70:1587-1593.
172. Etz CD, Welp HA, Tjan TD, Hoffmeier A, Weigang E, Scheld HH, Schmid C. Medically refractory pulmonary hypertension: Treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg 2007;83:1697-1705.
173. Martin J, Siegenthaler MP, Friesewinkel O, Fader T, van de Loo A, Trummer G, Berchtold-Herz M, Beyersdorf F. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study. Eur J Cardiothorac Surg 2004;25:971-977.
174. Petrofski JA, Hoopes CW, Bashore TM, Russell SD, Milano CA. Mechanical ventricular support lowers pulmonary vascular resistance in a patient with congential heart disease. Ann Thorac Surg 2003;75:1005-1007.
175. Zimpfer D, Zrunek P, Sandner S, Schima H, Grimm M, Zuckermann A, Wolner E, Wieselthaler G. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg 2007;31:698-702. Epub 2007 Feb 7.
176. Liden H, Haraldsson A, Ricksten SE, Kjellman U, Wiklund L. Does pretransplant left ventricular assist device therapy improve results after heart transplantation in patients with elevated pulmonary vascular resistance? Eur J Cardiothorac Surg 2009. [Epub ahead of print].
177. Pedemonte VO, Aránguiz Santander E, Torres HH, Merello NL, Vera PA, Díaz NR, Kaplán MJ. Right ventricular assistance with a centrifugal pump. Report of two cases. Rev Med Chil 2008;136:359-366. Epub 2008 Jun 3.
178. Damman K, Navis G, Smilde TD, Voors AA, Van Der Bij W, van Veldhuisen DJ, Hillege HL. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007;9:872-878. Epub 2007 Jun 22
179. Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L, Tognoni G. A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. Am Heart J 2007;153:1037-1047.
180. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928.
181. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
182. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study ofadding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-1263.
183. Damps-Konstańska I, Konstański Z, Jassem E. [Treatment of pulmonary hypertension]. Wiad Lek 2007;60:545-549.
184. Lunze K, Gilbert N, Mebus S, et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest 2006;36(Suppl):32-38.
185. Galiè N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan: results of the EARLY study. Lancet 2008;371:2093-2100.
186. Kuhlen R, Walbert E, Fränkel P, Thaden S, Behrendt W, Rossaint R. Combination of inhaled nitric oxide and intravenous prostacyclin for successful treatment of severe pulmonary hypertension in a patient with acute respiratory distress syndrome. Intensive Care Med 1999;25:752-754.
187. Pérez-Peñate GM, Juliá-Serdà G, Ojeda-Betancort N, García-Quintana A, Pulido-Duque J, Rodríguez-Pérez A, Cabrera-Navarro P, Gómez-Sánchez MA. Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension. J Heart Lung Transplant 2008;27:1326-1332. Epub 2008 Oct 26.
188. Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008;21:824-832. Epub 2008 Jul 9.
189. Lobato EB, Beaver T, Muehlschlegel J, Kirby DS, Klodell C, Sidi A. Treatment with phosphodiesterase inhibitors type III and V: Milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. Br J Anaesth 2006;96:317-322. Epub 2006 Jan 27.
190. Hoeper MM, Markevych I, Spiekerkotter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-863.
191. De Santo LS, Mastroianni C, Romano G, Amarelli C, Marra C, Maiello C, Galdieri N, Della Corte A, Cotrufo M, Caianiello G. Role of sildenafil in acute posttransplant right ventricular dysfunction: Successful experience in 13 consecutive patients. Transplant Proc 2008;40:2015-2018.
192. Benedict N, Seybert A, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007;29:2134-2153.